OVERVIEW

Keeping the Patient in the Center in Age-related Macular Degeneration (AMD) Care is organized by CME Outfitters, LLC.

Premiere Date: Thursday, November 21, 2019
Credit Expiration Date: Saturday, December 31 , 2020

This activity offers CE credit for:
• Physicians (CME)
• Pharmacists (ACPE)
• ABO (MOC)
• Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: 0376-0000-19-065-H01-P

Statement of Need:
Age-related macular degeneration (AMD) is the leading cause of legal blindness in adults over age 50, but the development of agents that target vascular endothelial growth factor (VEGF) has revolutionized its treatment. There are currently two FDA-approved agents (ranibizumab and aflibercept) and one off-label anti-VEGF agent (bevacizumab) being used to treat patients with AMD, and data from emerging anti-VEGF agents have also demonstrated efficacy in improving visual acuity. However, step therapy requirements pose significant barriers to patient access to approved anti-VEGF therapies.

The first part of this CME Outfitters Snack series on overcoming the challenges of prior authorization when treating patients with AMD features expert faculty discussing how to implement patient-centric care models that incorporate shared decision-making, which is imperative to educating patients on the benefits and risks of FDA-approved and off-label agents for the treatment of AMD.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Implement patient-centric care models that incorporate shared decision-making (SDM) to educate patients on the benefits and risks of FDA-approved and off-label agents for the treatment of AMD.
The following learning objective pertains only to those requesting CNE or CPE credit:
• Describe patient-centric care models that incorporate shared decision-making (SDM) to educate patients on the benefits and risks of FDA-approved and off-label agents for the treatment of AMD.